Furthermore, we analyzed public patient cohorts (GSE91061 for melanoma, ERP117672 for HCC) on anti-PD-1 treatment and found that PRMT3 expression is significantly higher in responders compared to non-responders [36, 65]. Here, PRMT3 is linked to hepatocellular carcinoma.